Outlook Therapeutics Appoints Kevin Lundquist as CFO

04:39 PM EDT, 08/27/2026 (MT Newswires) -- Outlook Therapeutics (OTLK) said late Thursday it appointed Kevin Lundquist as chief financial officer, effective Monday. Lundquist joins Outlook Therapeutics following the US Food and Drug Administration's approval of Lytenava, as the company builds the financial and operational infrastructure to support its planned US commercial launch. Lundquist most recently served as CFO of CapsoVision (CV). Lawrence Kenyon will step down as CFO effective Sept. 1 and continue to support Outlook Therapeutics as a non-executive employee through Sept. 30, the company added.